Search

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé: Le carcinome hépatocellulaire (CHC) se développe dans la majorité des cas sur un foie cirrhotique. Le dépistage du CHC permet un diagnostic plus précoce de CHC, un accès plus fréquent à des traitements à visée curative et une amélioration de la survie des patients. En France, le dépistage par échographie abdominale semestrielle est recommandé chez les patients cirrhotiques. Cependant, seulement 20 % des patients ont un diagnostic dans le cadre d'un programme de dépistage. En l'absence de dépistage, il peut s'agir de patients ayant une cirrhose connue mais non correctement suivie, ou de patients n'ayant pas de cirrhose ou de fibrose hépatique connue. Reconnaître les patients à risque de maladie chronique du foie et identifier la fibrose avancée chez ces patients sont des axes d'optimisation du dépistage du CHC. Hepatocellular carcinoma (HCC) develops in most cases in a cirrhotic liver. HCC screening allows for an earlier diagnosis of HCC, more frequent access to treatments with curative intents, and improved patient survival. In France, biannual abdominal ultrasound screening for HCC is recommended for cirrhotic patients. However, only 20% of patients are diagnosed with HCC in a screening program. In case of patients diagnosed outside a screening programm, it may be either because they have known cirrhosis but are not properly followed, or because they have no known cirrhosis or liver fibrosis. Recognizing patients at risk for chronic liver disease and identifying advanced fibrosis in these patients are areas for optimizing HCC screening. [ABSTRACT FROM AUTHOR]

Résumé: L'actualité en oncologie digestive a été riche aux eJFHOD 2020 et ce compte-rendu n'en rapporte qu'une sélection. Suite aux résultats de l'étude BEACON CCR, une nouvelle AMM européenne est délivrée pour l'encorafénib associé au cétuximab dans les cancers colorectaux avec mutation BRAF V600E en deuxième ligne. L'ADN tumoral circulant et la présence de dépôts tumoraux sont des facteurs pronostiques importants dans les cancers colorectaux localisés. Les arguments s'accumulent pour la place de l'immunothérapie dans les cancers de l'œsophage. La médecine personnalisée est prometteuse dans les cancers des voies biliaires alors que le Folfirinox est tenu en échec en première ligne dans l'essai de phase II AMEBICA. Enfin, les actualités dans le carcinome hépatocellulaire se poursuivent, la combinaison atézolizumab-bévacizumab est un nouveau standard de première ligne avec une autorisation temporaire d'utilisation de cohorte depuis le 20 juillet 2020, et les futurs essais cliniques évaluant la radiothérapie intra-artérielle sélective devront inclure une dosimétrie personnalisée. There was a lot of news in digestive oncology at eJFHOD 2020 and this report is only a selection.. Following the results of the BEACON CCR study, a new European Marketing Authorization has been issued for encorafenib combined with cetuximab in colorectal cancers with BRAF V600E mutation in the second line. Circulating tumor DNA and the presence of tumor deposits are important prognostic factors in localized colorectal cancers. There is growing evidence for the role of chekpoint inhibitors in esophageal cancer. Personalized medicine is promising in biliary tract cancers whereas Folfirinox fails in the first-line AMEBICA phase II trial. Finally, the atezolizumab-bevacizumab combination is a new first-line standard with temporary authorization for cohort use since July 20, 2020, and future clinical trials evaluating selective intra-arterial radiotherapy should include personalized dosimetry. [ABSTRACT FROM AUTHOR]

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)